Proposed Research Rule Faces Widespread Opposition in the US
In the United States, a proposed research rule put forth by Trump is encountering significant opposition from various groups, including patient advocates, scientists, bipartisan lawmakers, and pharmaceutical companies.
Miami Fort Lauderdale, FL, July 13, 2026 —
A proposed research rule, initiated during the Trump administration, is currently facing substantial opposition across the United States. The rule has drawn criticism from a diverse coalition of stakeholders, including patient advocacy groups, the scientific community, members of both major political parties, and the pharmaceutical industry.
Details regarding the specific provisions of the proposed rule and the precise nature of the opposition from each group were not provided in the summary. However, the breadth of opposition suggests significant concerns about the potential impact of the rule on research practices, patient welfare, or scientific advancement.
The involvement of pharmaceutical companies alongside patient advocates and scientists indicates a potentially wide-ranging debate over the future direction of research policy. Bipartisan lawmaker involvement further highlights the issue’s political significance.
Further information regarding the specific objections raised by patient advocates, scientists, lawmakers, and pharmaceutical companies, as well as the timeline for the rule’s consideration and potential amendments, is not available.
Story summarized from the original created by Joseph Choi,Nathaniel Weixel on thehill.com, see more information here.
Media gallery
